Preparation, Characterization, and Dissolution Rate In Vitro Evaluation of Total Panax Notoginsenoside Nanoparticles, Typical Multicomponent Extracts from Traditional Chinese Medicine, Using Supercritical Antisolvent Process
Table 2
Orthogonal array design OA16 (4)5 and experimental results.
Trial numbers
Concentration of TPNS solution (mg/mL)
Precipitation temperature (°C)
Precipitation pressure (MPa)
TPNS solution flow rate (mL/min)
CO2 flow rate (kg/h)
MPS (nm) ± SD ()
TSA (R1, Rb1, Rg1) (%)
1
1
1
1
1
0.99
8.5
263.3 ± 28.2
66.43 (6.89, 35.03, 24.51)
2
1
2
2
2
0.97
8.5
185.0 ± 16.1
57.63 (6.55, 23.88, 27.21)
3
1
3
3
3
0.96
8.5
155.9 ± 14.4
96.04 (9.48, 45.61, 40.95)
4
1
4
4
4
0.95
8.5
238.8 ± 26.2
89.49 (9.86, 41.27, 38.36)
5
2
1
2
3
0.96
8.5
229.5 ± 22.5
66.54 (6.13, 29.12, 31.29)
6
2
2
1
4
0.95
8.5
271.2 ± 32.8
51.29 (3.95, 29.08, 18.26)
7
2
3
4
1
0.99
8.5
239.7 ± 25.0
56.16 (5.55, 27.94, 22.67)
8
2
4
3
2
0.97
8.5
265.0 ± 25.9
36.97 (2.65, 18.64, 15.68)
9
3
1
3
4
0.95
8.5
214.5 ± 23.1
66.02 (6.44, 34.12, 25.46)
10
3
2
4
3
0.96
8.5
258.3 ± 24.7
71.78 (7.18, 37.47, 27.13)
11
3
3
1
2
0.97
8.5
354.1 ± 38.4
66.91 (6.55, 33.94, 26.42)
12
3
4
2
1
0.99
8.5
320.4 ± 21.5
71.81 (6.92, 36.85, 28.04)
13
4
1
4
2
0.97
8.5
218.7 ± 22.6
65.60 (6.92, 38.50, 20.18)
14
4
2
3
1
0.99
8.5
228.3 ± 20.5
57.02 (5.57, 29.12, 22.33)
15
4
3
2
4
0.95
8.5
325.7 ± 28.1
59.48 (6.59, 24.93, 27.96)
16
4
4
1
3
0.96
8.5
396.1 ± 40.0
45.99 (4.92, 22.11, 18.96)
MPS
210.75 ± 21.2
231.50 ± 24.1
321.18 ± 34.9
262.93 ± 23.8
251.35 ± 26.6
235.70 ± 23.5
265.15 ± 22.1
255.70 ± 25.8
286.83 ± 26.9
268.85 ± 26.5
215.93 ± 21.0
259.95 ± 25.4
292.20 ± 27.8
305.08 ± 28.4
238.88 ± 24.6
262.55 ± 27.6
81.45
73.58
105.25
7.23
Optimal level
TSA
77.398
66.148
57.655
62.855
52.740
59.430
63.865
56.777
69.130
69.647
64.012
70.088
57.023
61.065
70.757
66.570
24.658
10.217
13.102
13.311
= (mean particle size at )/4, the mean values of mean particle size for a certain factor at each level with standard deviation. . is the mole fraction of the antisolvent CO2 in the mixture.
